Company: SION
Filing Date: 2025-02-03
Form Type: S-1/A
Source: 0001193125-25-018825
Chunk: 239

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-02-03
Form: S-1/A
Chunk 239
---
 any additional directorships resulting from an increase in the number of directors will
be distributed among the three classes so that, as nearly as possible, each class will consist of one third of the directors. The division of our board of directors into three classes with staggered three-year terms may delay or prevent a change of
our management or a change in control.

This classification of our board of directors may have the effect of delaying or preventing changes in
control of our company.

Director Independence

Under the
listing standards, requirements and rules of The Nasdaq Stock Market LLC (the “Nasdaq Listing Rules”), independent directors must comprise a majority of our board of directors as a listed company within one year of the listing date.

Our board of directors has undertaken a review of the independence of each director. Based on information provided by each director concerning his or
her background, employment and affiliations, including family relationships, our board of directors has determined that none of the members of our board of directors, except Mr. Cloonan, have relationships that would interfere with the exercise of
independent judgment in carrying out the responsibilities of a director and that each of the directors, except Mr. Cloonan, is “independent” as that term is defined under the Nasdaq Listing Rules. Our board of directors has determined that
Mr. Cloonan, by virtue of his position as our current Chief Executive Officer, is not independent under applicable rules and regulations of the SEC and the Nasdaq Listing Rules. In making these determinations, our board of directors considered
the current and prior relationships that each non-employee director has with our company and all other facts and circumstances our board of directors deemed relevant in determining their independence,
including the beneficial ownership of our shares by each non-employee director and the transactions described in “Certain Relationships and Related Person Transactions.”

Board Diversity

Our nominating and corporate governance
committee and our board of directors may consider a broad range of factors relating to the qualifications and background of director nominees, such as a candidate’s character, judgment, skills, education, expertise and absence of conflicts of
interest, as well as diversity. The nominating and corporate governance committee and the full board of directors are committed to creating a board of directors with diversity, including diversity of expertise, experience, background and gender, and
are committed to identifying, recruiting and advancing candidates offering such diversity in future searches.

Board Leadership Structure and Board’s Role in Risk Oversight

Mr. Clancy is the current chair of our board of directors and